ClinicalTrials.gg
CompletedNCT01033305Updated Apr 19, 2012

Oral Ciclosporin for Colonic Release in Ulcerative Colitis (CyCol™)

A Phase 2 interventional study of CyCol™ and Placebo in Mild to Moderate Ulcerative Colitis, sponsored by Sigmoid Pharma. Completed at 22 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-04-19.

Sponsored by Sigmoid Pharma · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
118
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 215 studies in Colitis, Ulcerative with a site in United Kingdom — 29 open to participants now, 60 under way, 25 of them phase 3. Colitis, Ulcerative · United Kingdom.

Enrollment
101st of 178
118 · median 143
Started
2010
with 5 others
Phase 2
57 of 215
4 open now
Registered
21st of 215
by date

Among the 215 studies in Colitis, Ulcerative with a site in United Kingdom, this one is the 101st largest by enrollment of the 178 interventional ones that give a count, is one of 6 that started in 2010, is one of 57 in phase 2, and was the 21st registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

29 of the 215 studies in Colitis, Ulcerative with a site in United Kingdom are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 215 studies in Colitis, Ulcerative with a site in United Kingdom, or all of them as a file.
02

Study summary

This is a multi-center study in Ireland and United Kingdom to determine the effects, safety and tolerability of a drug called CyCol™ in improving mild to moderate ulcerative colitis (UC).

Informed consent will be obtained and following confirmation of eligibility and disease assessment, study participants will be randomised (allocated by chance) to take either CyCol™, or placebo, orally once every day for four weeks. Study visit assessments will include blood and stool tests, physical examinations and flexible sigmoidoscopies (inspection of the bowel wall using a flexible camera).

Half the participants will receive CyCol™ and half will receive placebo. At the end of treatment (4 weeks) study participants will be reassessed again and the findings in those who received CyCol™ will be compared with those who received placebo. Any side effects experienced during the study and the safety of treatment with CyCol™ will also be evaluated.

03

Conditions studied

  • Mild to Moderate Ulcerative Colitis

Browse trials for

Keywords

  • UC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged > 18 years
  • Diagnosis of mild to moderate diagnosis of UC involving at least the rectum and sigmoid colon
  • Clinical severity assessed at screening using the Disease Activity Index (DAI)
  • Clinical severity documented and confirmed by flexible sigmoidoscopy, within 7 days of starting study treatment
  • Signed and dated written .
  • Willing to maintain current UC medication dosing regimen from screening until the end of the 4-week treatment period.
  • Able and willing to refrain from intake of St. Johns Wort or any other prescription, over-the-counter, or herbal preparation that is known to affect cytochrome P450 metabolism throughout the 4-week treatment period.
  • Able and willing to refrain from intake of grapefruit or grapefruit juice or any other food or drink that is known to affect cytochrome P450 metabolism throughout the 4 week treatment period of the study.

Exclusion criteria

Exclusion Criteria:

  • Severe or fulminant UC.
  • UC limited to rectum only.
  • Any previous colonic surgery.
  • Any histological evidence of dysplasia on colonoscopic .
  • Women of who are unable or unwilling to use adequate methods to avoid pregnancy.
  • Previous unsuccessful ciclosporin therapy.
  • Biologic therapy within the past 2 months prior to study treatment.
  • Methotrexate therapy within 4 weeks of study treatment.
  • A treatment dose of greater than 10 mg/day prednisolone (or equivalent) within 4 weeks of study treatment.
  • Use of topical treatment (e.g. enemas) within 4 weeks of study treatment and unwilling to refrain from use of topical treatments from the screening visit until the end of the 4-week treatment period.
  • Significant renal impairment, hepatic impairment, uncontrolled hypertension, premalignant skin lesions or current , or any other severe co-morbid condition.
  • Known to ciclosporin or any of its .
  • Positive screening stool assay for Clostridium difficile, hemorrhagic E.coli 0157:H7, Salmonella or Shigella
  • Diagnosis of Crohn's colitis, ischemic colitis, NSAID-induced colitis, or radiation colitis.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
118 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Experimental
    CyCol™

    Drug: CyCol™

Interventions

  • Orally, once per day for 4 weeks

    Also known as: Ciclosporin

  • DrugPlacebo

    Orally, once per day for 4 weeks

    Also known as: Sugar Pill

06

What researchers measure

Primary outcomes

  1. Efficacy of CyCol™ in inducing clinical remission of mild to moderate Ulcerative Colitis.

    Time frame: 4 weeks

07

Study locations

22 sites
  • Cork University Hospital
    Cork, Co. Cork, Ireland
  • Mater Misercordiae University Hospital
    Dublin 7, Co. Dublin, Ireland
  • St. James's Hospital
    Dublin, Co. Dublin, Ireland
  • Clinical Science Institute
    Galway, Co. Galway, Ireland
  • The Adelaide and The Meath Hospital (Tallaght)
    Tallaght, Dublin Dublin 24, Ireland
  • St. Vincent's University Hospital
    Dublin 4, Ireland
  • Beaumont Hospital
    Dublin 9, Ireland
  • MidWestern Regional Hospital
    Limerick, Ireland
  • Queen Elizabeth Hospital
    Birmingham, B15 2TH, United Kingdom
  • Sandwell and West MidlandsHospitals NHS Trust
    Birmingham, B71 4HJ, United Kingdom
  • Bristol Royal Infirmary
    Bristol, BS2 8HW, United Kingdom
  • Conventry university Hospital
    Coventry, CV2 2DX, United Kingdom
  • Leeds General infirmary
    Leeds, United Kingdom
  • Royal Liverpool and Broadgreen University Hospitals NHS Trust
    Liverpool, L7 8XP, United Kingdom
  • University College Hospital London
    London, NW1 2BU, United Kingdom
  • Kings College London
    London, SE5 9RS, United Kingdom
  • St. Mark's Hospital
    London, United Kingdom
  • Manchester Royal Infirmary
    Manchester, M13 9WL, United Kingdom
  • George Elliot hospital
    Nuneaton, CV10 7DJ, United Kingdom
  • John Radcliff Hospital
    Oxford, OX3 9DU, United Kingdom
  • Royal Shrewsbury Hospital
    Shrewsbury, SY3 8XQ, United Kingdom
  • New Cross Hospital
    Wolverhampton, WV10 0QP, United Kingdom
08

References and documents

Related links

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2010, a primary completion of Aug 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2009
First posted
Dec 16, 2009
Start
Mar 2010
Primary completionActual
Aug 2011
CompletionActual
Sep 2011
Last update
Apr 19, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01033305
Lead sponsor
Sigmoid Pharma
Responsible party
Sponsor
First posted
Dec 16, 2009
Start date
Mar 2010
Primary completion
Aug 2011
Completion
Sep 2011
Last update
Apr 19, 2012

Study contacts

Diarmuid O'Donoghue, Prof
principal investigator · St Vincent's University Hospital
Stuart Bloom, M.D.
principal investigator · University College Hospital NHS Trust

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclosporine

Start the discussion